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Abstract: Gelam honey exerts anti-inflammatory and antioxidant activities and is thought 
to have potent effects in reducing infections and healing wounds. The aim of this study was 
to investigate the effects of intravenously-injected Gelam honey in protecting organs from 
lethal doses of lipopolysaccharide (LPS). Six groups of rabbits (N = 6) were used in this 
study. Two groups acted as controls and received only saline and no LPS injections. For 
the test groups, 1 mL honey (500 mg/kg in saline) was intravenously injected into two 
groups (treated), while saline (1 mL) was injected into the other two groups (untreated); 
after 1 h, all four test groups were intravenously-injected with LPS (0.5 mg/kg). Eight 
hours after the LPS injection, blood and organs were collected from three groups (one from 
each  treatment  stream)  and  blood  parameters  were  measured  and  biochemical  tests, 
histopathology, and myeloperoxidase assessment were performed. For survival rate tests, 
rabbits from the remaining three groups were monitored over a 2-week period. Treatment 
with honey showed protective effects on organs through the improvement of organ blood 
parameters, reduced infiltration of neutrophils, and decreased myeloperoxidase activity. 
Honey-treated rabbits also showed reduced mortality after LPS injection compared with 
untreated  rabbits.  Honey  may  have  a  therapeutic  effect  in  protecting  organs  during 
inflammatory diseases. 
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1. Introduction 
Honey is a natural, sweet and viscous fluid produced by bees from floral nectar, which comprises 
more than 400 different chemical compounds [1], including proteins, enzymes, organic acids, mineral 
salts,  vitamins,  phenolic  acids,  flavonoids,  free  amino  acids,  and  small  quantities  of  volatile 
compounds [2]. Historically, honey has been used as a treatment for a broad spectrum of injuries, 
including wounds, burns and ulcers [3,4]. Honey has  also been reported to stimulate the immune 
system  (monocytes,  neutrophils)  [5–7].  It  also  clears  infection  by  boosting  the  immune  system, 
exerting anti-inflammatory and antioxidant activities, and stimulating cell growth [8]. Gelam honey 
inhibits nitric oxide (NO) and cytokine release both in vitro and in vivo [9,10]. 
Lipopolysaccharide (LPS) stimulates innate immune responses that mediate the cellular release of 
NO  and  various  proinflammatory  cytokines  and  chemokines,  as  well  as  inducing  macrophage 
migration and contributing to the pathogenesis of sepsis [11]. Injection of animals with high doses of 
LPS  causes  multiple  organ  failure,  characterized  by  circulatory  failure,  systemic  hypotension,  
hypo-reactivity to vasoconstrictors, subsequent problems with organ perfusion and the development of 
functional  abnormalities  [12],  which  reflect  systemic  inflammatory  response  syndrome  and  septic 
shock, rather than endotoxin-induced failure of lung, liver, and renal tissues [13]. 
Sepsis is the leading cause of death worldwide, with more than 750,000 cases of sepsis diagnosed 
annually  and  mortality  rates  ranging  from  30  to  60%;  this  systemic  inflammation  accounts  for 
approximately 200,000 deaths per year in the US alone [14]. Sepsis causes endothelial injury and 
neutrophil infiltration into tissues, leading to local injury, disturbed capillary blood flow and enhanced 
microvascular permeability, disseminated intravascular coagulation, circulatory collapse, hypoxia and, 
ultimately,  multiple  organ  failure  [15].  The  aim  of  the  current  study  was  to  investigate  whether 
intravenous injection of honey can protect organs from lethal doses of LPS that induce sepsis in rabbits. 
2. Results 
2.1. Effect of Gelam Honey on Biochemical and Hematological Tests, Histopathology, and MPO Activity 
Intravenous  injection  of  honey  resulted  in  potent  protection  against  a  lethal  dose  of  LPS  as 
evidenced by improved liver, kidney, cardiac and lipid profiles. Compared to the untreated group, the 
honey-treated  group  showed  significant  reductions  in  the  levels  of  alanine  transaminase  (ALT), 
aspartate  aminotransferase  (AST),  γ-glutamyltransferase  (γ-GT),  alkaline  phosphatase  (ALP), 
cholesterol, triglycerides, creatine kinase, creatinine, urea and amylase. Moreover, the honey-treated 
group showed higher RBC, WBC and thrombocyte counts than the untreated group (Table 1). Arterial 
blood gases and pH values were determined for all groups (Table 1). The honey-treated group showed 
mild respiratory alkalosis, while in the untreated group, the arterial blood pH was closer to acidosis. 
Blood pCO2 was lowered by LPS injection, but to the same level in the honey-treated group and Int. J. Mol. Sci. 2012, 13  6372 
 
 
untreated group, indicating that honey injection did not prevent the reduction in pCO2. Blood HCO3 
and PO2 were higher in the honey-treated group than in the untreated group. There was clear evidence 
of hypoxia in the untreated group, as shown by the reduction in the pO2 value (Table 1). Neutrophil 
infiltration was reduced in the treated group; however, MPO activity in the honey-treated group was 
significantly lower than that in the untreated group (Figure 1). In addition, more histopathological 
changes  were  observed  in  the  untreated  group,  as  evidenced  by  cellular  infiltration  of  the  lungs  
(Figure 2). Finally, 66.7% of rabbits in the untreated group died compared with 33.3% in the treated 
group (Figure 3). Survival rates were monitored over a 2-week period. 
Figure 1. Effect of honey on neutrophil infiltration into lung tissues induced by a lethal 
dose of lipopolysaccharide (LPS). Myeloperoxidase (MPO) activity was measured in all 
groups (n = 6 per group) 8 h after LPS injection. MPO activity was significantly higher in 
the untreated (saline + LPS 0.5 mg/kg) group than in the treated (honey, 500 mg/kg + LPS 
0.5 mg/kg) group. *** P < 0.002. 
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Figure 2. (A) Immune-cell infiltration and tissue damage in the lungs of rabbits from the 
untreated group 8 h after LPS injection; (B) Immune-cell infiltration and tissue damage in 
the lungs of rabbits from the honey-treated group 8 h after LPS injection; (C) Normal lung 
tissues in rabbits treated with saline. Hematoxylin and eosin staining; magnification 10× ; 
scale bar, 30 µm. 
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Figure 3. The effect of honey on the survival of rabbits injected with LPS (0.5 mg/kg). 
Rabbits in all three groups (n = 6 per group) received 1 mL injections of LPS into the ear 
vein.  The  survival  rates  in  the  untreated  and  honey-treated  (60,  300,  and  600  mg/kg) 
groups  injected  with  0.5  mg/kg  LPS  are  shown  as  black  triangles  and  black  squares, 
respectively. Control rabbits received saline only (black circles). Honey was administered 
daily for 3 days after LPS treatment. Kaplan–Meier analysis showed significantly better 
survival rates in the honey-treated group (500 mg/kg + LPS) than in the untreated LPS 
group (LPS). *** P < 0.005.  
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Table  1.  Assessment  of  organ  damage  in  the  control  group  and  in  honey-treated  and 
untreated groups given a single intravenous injection of lipopolysaccharide. 
Parameter  Normal Rabbits (N = 6)  Untreated (N = 6)  Honey-treated (N = 6) 
Urea (mmol/L)  5.85 ±  0.20  55.85 ±  2.5  10.5 ±  0.23 
a 
Creatinine (mmol/L)  83.71 ±  2.5  154 ±  6.16  72 ±  2.87 
a 
ALT (IU/L)  54.125 ±  1.8  108.75 ±  3.6  78.75 ±  1.98 
a 
AST (IU/L)  27.75 ±  0.9  577.33 ±  19.2  231.5 ±  7.6 
a 
ALP (IU/L)  131.5 ±  4.1  542.75 ±  15.5  308.75 ±  11.4 
a 
GGT (IU/L)  10 ±  0.32  38.4 ±  0.6  25 ±  1.7 
b 
Triglyceride (mmol/L)  0.885 ±  0.03  10.434 ±  0.4  2.47 ±  0.13 
a 
Total cholesterol (mmol/L)  1.1125 ±  0.04  3.16 ±  0.1  1.8 ±  0.08 
c 
HDL (mmol/L)  0.65 ±  0.03  0.25 ±  0.006  0.545 ±  0.02 
b 
LDL (mmol/L)  0.202 ±  0.005  0.45 ±  0.01  0.32 ±  0.012 
Creatine kinase (IU/L)  1327.4 ±  5.3  2168.3 ±  34  998.6 ±  26.8 
a 
pH (KPa)  7.38 ±  0.3  7.36 ±  0.3  7.5 ±  0.27 
b 
pCO2 (KPa)  4.3 ±  0.17  3 ±  0.12  3 ±  0.12 
pO2 (KPa)  16.21 ±  0.53  7.65 ±  0.23  19.3 ±  0 .77 
b 
HCO3 (mmol/L)  19 ±  0.71  15 ±  0.51  19 ±  0.54 
a 
Platelet (10e9/L)  194.3 ±  6.4  144.5 ±  4.3  183.4 ±  7.6 
b 
Amylase (IU/L)  181.3 ±  7.2  215.5 ±  6.2  180 ±  5.2 
b 
RBC (10e12/L  9.27 ±  0.31  4.83 ±  0.15  8.3475 ±  0.32 
a 
WBC (10e9/L)  15 ±  0.6  6.05 ±  0.25  11.65 ±  0.36 
a 
a P < 0.001; significant effect of untreated group vs. honey-treated group; 
b P < 0.003; significant 
effect of untreated group vs. honey-treated group; 
c P < 0.005; significant effect of untreated group vs. 
honey-treated group. Int. J. Mol. Sci. 2012, 13  6374 
 
 
3. Discussion 
Previous  studies  have  shown  that  honey  has  antioxidant,  antimicrobial,  and  anti-inflammatory  
properties [16]. This study identified a protective role for honey against systemic damage induced by 
lethal doses of LPS in a rabbit model. These effects were evidenced by decreased blood chemistry 
parameters  of  organ  dysfunction,  decreased  cellular  infiltration  into  the  tissues,  and  decreased 
mortality. To the best of our knowledge, this is the first study showing that honey can protect organs 
from lethal doses of LPS. The results indicate that honey can counteract the effects of LPS, which is a 
compound that can lead to organ and multi-organ failure. 
When immune responses are insufficient, infections can lead to sepsis [17]. Many studies report 
that sepsis is a complicated pathophysiological and immunological process that causes alterations in 
the structure and characteristics of blood cells and tissues, leading to multi-organ failure. Lethal doses 
of LPS in animals induce a variety of organ and systemic changes that lead to organ failure and, 
ultimately, to death [18,19]. Previous studies have shown that the acute exposure of rabbits to LPS is 
associated with necrosis in organs such as the lungs and liver. The presence of polymorphonuclear 
leukocytes  (PMNLs)  was  noted  in  association  with  necrosis  in  the  lung  and  liver  as  well  as  an 
apoptotic cellular appearance in the LPS group. In addition, LPS stimulates the production of many 
cellular  substances,  such  as  cytokines,  NO,  vasoactive  peptides,  pro-coagulant  factors,  and 
prostaglandins, both in vitro and in vivo [15]. Earlier reports indicate that LPS and cytokines, such as 
TNF-α and IL-1β, induce apoptotic necrosis in cells and tissues [20,21]. Furthermore, LPS activates 
NF-κB,  which  activates  many  mediators  including  pro-  and  anti-inflammatory  cytokines  such  as  
TNF-α  ,IL-1β,  IL6  and  IL-10  [22].  These  cytokines  enhance  vascular  permeability,  stimulate  the 
expression of adhesion molecules on endothelial cells, and induce infiltration of cells from the blood to 
tissues [23]. Sepsis-induced acute lung injury is a major clinical problem with significant morbidity 
and mortality [24–26]. PMNLs are thought to contribute significantly to the pathophysiologic features 
of  acute  lung  injury  [27–31].  A  pathological  hallmark  of  acute  lung  injury  is  subsequent  tissue 
infiltration of neutrophils and pulmonary microvascular sequestration [32,33]. Enhanced pulmonary 
neutrophil sequestration and infiltration during sepsis changes the neutrophil profile by increasing 
neutrophil surface expression and activating cell-cell adhesion molecules, and enhancing the release of 
soluble  mediators,  production  of  cytokines,  and  generation  of  reactive  oxygen  species,  NO,  and 
ONOO
− [34–38]. Acute lung injury is characterized by increased MPO activity, a marker of neutrophil 
infiltration, increased expression and activity of cytokines and iNOS, high-protein pulmonary edema, 
and oxidant stress [31,39]. Pulmonary microvascular neutrophil sequestration and tissue infiltration are 
hallmarks of the pathogenesis of acute lung injury [33,40,41]. The present study is in agreement with 
previous  studies  showing  that  sepsis  induces  changes  in  pulmonary  microvascular  neutrophil 
sequestration and alveolar neutrophil infiltration, [34–36,42] as clearly shown in the untreated group 
but not in the honey-treated group (Figures 1 and 2). In addition, honey treatment decreased lung 
injury by inhibiting MPO activity. Therefore, as reported in our previous studies, honey may decrease 
lung injury through systemic inhibition of cytokines such as PGE2 and NO [9,10].  
In this study, the reductions in RBC, WBC, and platelet counts observed in the untreated group 
confirm those seen in earlier reports [43,44]. Treatment with honey significantly attenuated the severe 
reductions  in  blood  counts  (WBC  and  RBC)  and  thrombocytopenia,  suggesting  that  honey  has  a Int. J. Mol. Sci. 2012, 13  6375 
 
 
protective role against sepsis-induced disseminated intravascular coagulation. LPS causes disseminated 
intravascular coagulation, which is associated with coagulation disorders and loss of platelets. In the 
liver, LPS causes increases in AST, ALT, γ-GT, and lipid profiles [43,45–49], which are all markers of 
hepatic  damage  [44,49,50].  Our  results  confirm  that  sepsis  caused  liver  failure,  as  shown  by 
significantly elevated serum levels of AST, ALP, and γ-GT in the untreated group; honey inhibited 
these increases. Improved liver function tests after honey treatment indicate that honey may potentially 
protect liver cells from sepsis. Lipid profiles showed that cholesterol, triglycerides, and LDL levels 
were significantly increased in the LPS-induced untreated sepsis group but not in the honey-treated 
group. However, the HDL levels were significantly lower in the untreated group. Injection of LPS into 
animals  induces  renal  dysfunction  characterized  by  increased  blood  urea  nitrogen  and  plasma 
creatinine levels [45,51]. Urea nitrogen and plasma creatinine levels were increased by LPS injection, 
but were lower in the honey-treated group than in the untreated group. Both our previous studies and 
the  above  results  show  that  LPS  increased  the  levels  of  hepatic  damage  markers,  modified  lipid 
metabolism, and increased lipid profiles, hematological values, and renal dysfunction [52]. Our results 
also show that Gelam honey protects organs from immune responses induced by lethal doses of LPS. 
Our previous study showed that Gelam honey contains many phenolic compounds with antioxidant and 
anti-inflammatory activity. In addition, its inhibitory effect on cytokines (TNF-α, IL-1β, and IL-10), 
high-mobility group protein 1 (HMG-1), and NO both in vitro and in vivo were studied [9,10,53]. 
Gelam honey also showed potent induction of HO-1, a molecule related to oxidative stress [53]. These 
activities, including the inhibition of cytokines and NO during severe sepsis, suggest that honey may 
be useful for the treatment of sepsis. The phenolic compounds in Gelam honey play a role in protecting 
tissues from LPS and free radicals due to their antioxidant activity, such as scavenging oxygen radicals, 
NO,  and  lipid  radicals  [54],  and  preventing  cancer  and  various  inflammatory  disorders,  such  as 
arthritis and septic shock induced by endotoxemia [55–58]. The beneficial effects of honey, which 
include preventing histological changes and hypoxia in the organs of rabbits treated with LPS, may be 
directly related to its antioxidant activity, or indirectly related to the inhibition of PMNL chemotaxis, 
thereby preventing the production of the chemotactic agents implicated in tissue damage. We showed 
previously that Gelam honey has potent antioxidant activity and inhibits mediators of inflammation, 
such  as  cytokines,  NO  and  PGE2  [9,10,53].  Allergic  reactions  constitute  a  potentially  serious 
contraindication for injecting people with honey because honey contains bee-secreted and plant pollen-
derived proteins that are known to induce allergic reactions [59].  
4. Experimental Section 
4.1. Preparation of Honey  
Malaysian Gelam honey (Melaleuca spp.) was purchased from the department of Agriculture, Batu 
Pahat, Johor, Malaysia, and sent to Malaysian Nuclear Agency for sterilization using a Cobalt-60 
source (Model JS10000). Honey was mixed with saline and filtered through a 0.20 µm syringe filter 
before injection. 
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4.2. Animals 
Mice Balb/c mice (6–7 weeks of age) and New Zealand white male rabbits weighing 25 g and 2 kg, 
respectively,  were  kept  in  individual  cages  under  standard  conditions  (12  h  light  and  12  h  dark 
conditions); water and chow diet were available ad libitum. The study was carried out in accordance 
with the University of Malaya Animal Ethics Committee guidelines for animal experimentation and 
followed the approved protocols outlined in the project license (ANES/14/07/2010/MKAK (R)). 
4.3. Toxicity Tests  
The toxicity of Gelam honey was evaluated in mice (n = 8) for 1 month prior to the study. Four 
different doses of honey (10, 60, 300, and 600 mg/kg diluted in saline) were administered daily by 
injection into the tail vein (final volume, 100 µ L). The control group received a similar volume of 
saline. Mice were observed for 3 h after injection. Symptoms and mortality were recorded for all 
groups.  At  the  end  of  the  study,  all  mice  were  sacrificed,  and  blood  and  organs  were  collected. 
Compared with the control group, the treated groups showed no abnormalities on biochemical and 
histopathological analysis of the liver, lungs, and kidneys (data not shown). 
4.4. Induction of an Immune Response in Rabbits by LPS Stimulation and Treatment with Honey  
New Zealand white male rabbits were divided into six groups (N = 6) of six animals (n = 6) and 
each group was treated as described below. An immune response was  induced in four groups by 
intravenous injection of 0.5 mg/kg LPS (B: 0111; Sigma, St. Louis, MO, USA) diluted in saline. One 
hour before LPS injection, honey (500 mg/kg diluted in saline) was injected into the rabbits from two 
groups (treated group), while saline was injected into the rabbits from another two groups (untreated 
groups). The two remaining groups acted as negative controls and were given saline only and no LPS. 
All doses were administered in a final volume of 1 mL and were mixed immediately prior to injection. 
Three  groups,  one  from  each  treatment  stream,  were  used  for  biochemical  and  histopathological 
studies and assessment of myeloperoxidase (MPO) activity as described below, while the remaining 
three groups were used to assess survival rates. Survival was monitored every 12 h for 15 days. 
4.5. Biochemical Analysis 
Blood  samples were  collected  from  the ears of rabbits  after 8 h of  LPS injection. Serum was 
separated by centrifugation at 3000 ×  g at 23 ° C, and hematological and biochemistry analysis were 
performed using an automated hematology cell counter analyzer (Sysmex XE-2100, Sysmex America, Inc.) 
and  Advia  2400  Chemistry  System  (Siemen,  Eschborn,  Germany),  respectively,  in  the  clinical 
diagnostic  laboratory  at  University  of  Malaya  Medical  Center.  Biochemical  analyses  included 
measurement of glucose, liver, and kidney functions. The parameters used for hematological analysis 
were red blood cell count (RBC), white blood cell count (WBC), and platelet counts. Arterial blood 
samples were collected to measure pH, pO2, pCO2, and HCO3 using a blood gas analyser at the same 
time as the other biomedical tests were performed.  
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4.6. Myeloperoxidase Assay 
Neutrophil  infiltration  into  the  lungs  was  monitored  by  measuring  MPO  activity  as  previously 
reported [60]. Briefly, tissue specimens were homogenized at 50 mg/mL in PBS (50 mM, pH 6.0) 
containing 0.5% exadecyltrimethylammonium bromide (Sigma-Aldrich). Samples were freeze-thawed 
three times and centrifuged at 13,000 rpm for 20 min. The supernatants were diluted 1:30 in assay 
buffer (50 mM PBS pH 6.0 containing 0.167 mg/mL o-dianisidine; (Sigma-Aldrich) and 0.0005% 
H2O2),  and  the  colorimetric  reaction  was  measured  at  450  nm  for  between  1  and  3  min  in  a 
spectrophotometer (Microplate reader, Model 680, Life Science Research, Bio-Rad). MPO activity/g 
of wet tissue was calculated as follows: MPO activity (U/g wet tissue) = (A450) (13.5)/tissue weight (g), 
where A450 is the change in the absorbance of 450 nm light between 1 and 3 min after the initiation of 
the  reaction.  The  coefficient  13.5  was  empirically  determined  such  that  1  U  MPO  activity 
corresponded to the amount of enzyme that reduced 1 μmol peroxide/min. 
4.7. Histopathology 
Liver, lung, heart, and kidney tissues were fixed in 10% formalin after the organs were dehydrated 
using graded ethanol solutions, cleared with xylene, paraffin embedded, sectioned, and stained with 
hematoxylin and eosin. Pathological changes were evaluated under a light microscope by a pathologist. 
4.8. Statistical Analysis 
All data are expressed as the mean ±  confidence interval. Data were analysed using GraphPad prism 
statistical software (San Diego, CA, USA) for non-parametric analysis of variance. Kaplan–Meier 
analysis was used to compare survival rates. Differences were considered statistically significant at  
P < 0.05. 
5. Conclusions  
In summary, Gelam honey protects organs from lethal doses of LPS by improving organ functions, 
reducing infiltration by PMNs that cause tissue damage, reducing MPO activity and increasing the 
survival rate. 
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